VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
XNCR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
XNCRXencor, Inc.
$34.50$2.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksXNCRFinancials

Xencor, Inc. (XNCR) Income Statement

15Y historyFree accessUpdated daily

Revenue and margins are highly volatile, with gross margin oscillating between roughly -159% and 100% and operating losses persisting in most quarters despite the 3Q26 revenue rebound to $116.5M.

Income StatementBalance SheetCash FlowRatios

XNCR Income Statement

Annual statement

XNCR Income Statement

Xencor, Inc. (XNCR) annual income statement — 15-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Sales/Revenue200.49M125.58M110.49M174.62M164.58M275.11M122.69M156.7M40.6M35.71M87.52M27.76M9.52M10.17M9.52M6.85M
Revenue Growth %19.8%13.65%-36.72%6.1%-40.18%124.23%-21.7%285.93%13.7%-59.2%215.25%191.62%-6.41%6.8%39.06%-
Cost of Goods Sold5.14M10.51M227.69M0199.56M192.51M169.8M118.59M97.5M71.77M51.87M34.14M18.52M17M12.67M0
COGS % of Revenue-8.37%206.06%-121.26%69.97%138.39%75.68%240.13%200.98%59.27%122.97%194.5%167.13%133.01%-
Gross Profit195.35M115.06M-117.19M174.62M-34.98M82.6M-47.11M38.11M-56.9M-36.06M35.65M-6.38M-9M-6.83M-3.14M6.85M
Gross Margin %97.43%91.63%-106.06%100%-21.26%30.03%-38.39%24.32%-140.13%-100.98%40.73%-22.97%-94.5%-67.13%-33.01%100%
Gross Profit Growth %-198.18%-167.12%599.13%-142.35%275.35%-223.61%166.98%-57.78%-201.16%658.92%29.1%-31.75%-117.18%-145.9%-
Operating Expenses341.04M292.57M61.22M306.98M47.49M38.84M29.69M24.29M119.97M89.27M64.98M46.1M25.98M20.69M15.75M16.3M
OpEx % of Revenue-232.98%55.4%175.8%28.85%14.12%24.2%15.5%295.48%249.99%74.25%166.05%272.87%203.42%165.41%238.01%
Selling, General & Admin60.49M63.64M58.89M53.38M47.49M38.84M29.69M24.29M22.47M17.5M13.11M11.96M7.46M3.69M3.09M3.64M
SG&A % of Revenue-50.68%53.29%30.57%28.85%14.12%24.2%15.5%55.35%49.01%14.98%43.08%78.37%36.3%32.4%53.12%
Research & Development285.69M239.43M227.69M253.6M199.56M192.51M169.8M118.59M97.5M71.77M51.87M34.14M18.52M17M12.67M12.66M
R&D % of Revenue-190.67%206.06%145.23%121.26%69.97%138.39%75.68%240.13%200.98%59.27%122.97%194.5%167.13%133.01%184.89%
Other Operating Expenses-2M-10.51M-225.36M0-199.56M-192.51M-169.8M-118.59M8.96M4.17M2.08M746K44K31K86K65K
Operating Income-145.69M-177.5M-178.41M-132.36M-82.47M43.77M-76.8M13.82M-79.37M-53.56M22.54M-18.34M-16.46M-10.52M-6.23M-9.45M
Operating Margin %-72.67%-141.35%-161.47%-75.8%-50.11%15.91%-62.59%8.82%-195.48%-149.99%25.75%-66.05%-172.87%-103.42%-65.41%-138.01%
Operating Income Growth %-0.51%-34.79%-60.49%-288.44%156.99%-655.53%117.42%-48.18%-337.63%222.91%-11.43%-56.44%-68.86%34.09%-
EBITDA-135.87M-166.99M-166.3M-120.86M-73.67M51.26M-71M18.12M-76.12M-51.53M24.01M-17.23M-15.57M-9.81M-5.7M-8.85M
EBITDA Margin %-67.77%-132.98%-150.51%-69.22%-44.77%18.63%-57.87%11.56%-187.47%-144.3%27.43%-62.05%-163.6%-96.43%-59.88%-129.14%
EBITDA Growth %-24.77%-0.41%-37.59%-64.05%-243.73%172.19%-491.81%123.81%-47.71%-314.66%239.37%-10.59%-58.78%-72%35.52%-
D&A (Non-Cash Add-back)9.82M10.51M12.11M11.5M8.8M7.49M5.79M4.3M3.25M2.03M1.47M1.11M882K711K527K607K
EBIT-92.04M-57.49M-198.28M-113.46M-54.49M82.64M-76.8M13.82M-79.37M-42.73M46.14M-17.58M-16.41M-59.05M-6.13M-9.35M
Net Interest Income-2.16M-4.4M-4.71M18.63M4.82M849K7.26M13.62M9.09M4.18M2.07M731K24K-1.2M-2.45M-1.82M
Interest Income21.36M27.52M31.93M18.63M4.82M862K7.26M13.62M9.1M4.19M2.09M744K33K14K11K34K
Interest Expense23.52M31.93M36.64M0013K0016K13K21K13K9K1.21M2.46M1.85M
Other Income/Expense30.13M87.87M-56.52M12.73M27.96M38.86M7.46M13.36M8.96M4.17M2.08M746K35K-49.74M-2.36M-1.75M
Pretax Income-115.56M-89.42M-234.92M-119.63M-54.51M82.63M-69.33M27.19M-70.41M-49.39M24.62M-17.59M-16.42M-60.26M-8.59M-11.2M
Pretax Margin %-57.64%-71.21%-212.61%-68.51%-33.12%30.04%-56.51%17.35%-173.41%-138.3%28.13%-63.37%-172.5%-592.39%-90.24%-163.57%
Income Tax2.3M2.5M1.62M13.66M673K00312K0-463K991K00533K00
Effective Tax Rate %-1.99%-2.8%-0.69%-11.42%-1.23%0%0%1.15%0%0.94%4.03%0%0%-0.88%0%0%
Net Income-117.86M-91.92M-232.62M-133.13M-55.18M82.63M-69.33M26.88M-70.41M-48.92M23.63M-17.59M-16.42M-60.26M-8.59M-11.2M
Net Margin %-58.79%-73.2%-210.53%-76.24%-33.53%30.04%-56.51%17.15%-173.41%-137%26.99%-63.37%-172.5%-592.39%-90.24%-163.57%
Net Income Growth %15.05%60.48%-74.73%-141.27%-166.78%219.18%-357.98%138.17%-43.91%-307.09%234.29%-7.12%72.75%-601.16%23.29%-
Net Income (Continuing)-117.86M-91.92M-236.54M-133.3M-55.18M82.63M-69.33M26.88M-70.41M-38.49M45.13M-17.59M-16.42M-60.26M-8.59M-11.2M
Discontinued Operations0000000000000000
Minority Interest00-3.58M337K000000000000
EPS (Diluted)-1.50-1.24-3.58-2.08-0.931.37-1.110.46-1.31-1.050.56-0.45-0.52-1.92-0.51-0.67
EPS Growth %15.43%65.36%-72.12%-123.66%-167.88%223.42%-341.3%135.11%-24.76%-287.5%224.44%13.46%72.92%-276.47%23.88%-
EPS (Basic)--1.24-3.58-2.08-0.931.42-1.110.48-1.31-1.050.57-0.45-0.52-1.92-0.51-0.67
Diluted Shares Outstanding78.35M74.24M65.04M60.5M59.65M60.5M57.21M58.47M53.94M46.82M42.39M39.02M31.43M31.35M16.69M16.69M
Basic Shares Outstanding76.22M74.24M65.04M60.5M59.65M58.38M57.21M56.53M53.75M46.82M41.27M39.02M31.39M31.35M16.69M16.69M
Dividend Payout Ratio----------------

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Lumpy collaboration revenue dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Lumpy Collaboration Revenue Drives Volatility

Based on the reported quarterly figures, Xencor's revenue swung from $70.0M in 4Q24 to $4.5M in 1Q26 and then rebounded to $116.5M in 3Q26, indicating growth driven by irregular milestone and upfront payments rather than steady royalty expansion.

The quarterly series suggests that top-line movements reflect the timing of partner-controlled events rather than a consistent underlying growth rate. The 3Q26 spike appears to be a discrete collaboration recognition event, which may not be repeatable and warrants investigation before extrapolating the trend. Investors should monitor whether royalty revenue alone can sustain the cost base over successive quarters.

Gross Margin Reflects Royalty Mix Shifts

The reported gross margin oscillated between roughly -159% and 100% over the period, with the 3Q25 negative figure of -158.9% coinciding with a $54.4M cost line that the data appears to classify as cost of revenue.

Gross margin behavior appears to reflect the timing of collaboration cost recognition rather than a structural pricing or cost shift. Quarters with zero reported COGS produce 100% margins, which suggests the metric is highly sensitive to classification rather than operating efficiency. The reported gross margin should therefore be interpreted cautiously and not as a stable indicator of pricing power.

Operating Losses Persist Despite Revenue Gains

Based on the reported TTM figures, operating margin stands at -141.4%, and R&D spending of $84.3M in 3Q26 against $9.4M of SG&A indicates that cost growth remains concentrated in clinical development.

The R&D-to-SG&A ratio points to a high fixed-cost base dominated by clinical execution, which limits operating leverage even when revenue rises. Operating income turned positive only in 3Q26 at $22.9M, a single quarter whose durability remains unproven. Investors should monitor whether R&D intensity moderates as internal late-stage programs advance.

Net Income Dependent on Non-Operating Items

Reported net income of $39.4M in 3Q26 exceeded operating income of $22.9M, while EPS of $0.50 and a 33.8% net margin appear inconsistent with the -141.4% TTM operating margin, suggesting non-operating or one-time gains.

The gap between operating and net income in 3Q26 suggests material non-operating contributions, potentially including interest income or other gains not evident in the operating line. Stock-based compensation of roughly $9M to $19M per quarter is material relative to reported losses and may distort underlying earnings quality. The reconciliation of these items warrants further investigation before the 3Q26 profit is treated as a run-rate.

Sustained Losses Challenge Platform Thesis

Persistent quarterly losses across most of the ten-quarter window, with net losses of $128.9M in 1Q26 and cumulative R&D above $60M per quarter, raise the question of whether royalty and collaboration income can fund the pipeline without further capital.

A bearish reading would emphasize that profitable quarters appear episodic and tied to partner events, while R&D commitments remain structurally elevated. If collaboration payments slow, the reported cost base suggests cash consumption could accelerate, potentially requiring dilutive financing. The absence of current cash and runway data in the supplied information limits how firmly this risk can be sized.

XNCR — Frequently Asked Questions

Quick answers to the most common questions about buying XNCR stock.

What was Xencor, Inc.'s (XNCR) revenue in 2025?

For fiscal year 2025, Xencor, Inc. (XNCR) reported total revenue of $125.6M. This represents a 1733.5% increase compared to $6.8M in 2011.

Is Xencor, Inc. (XNCR) profitable?

Xencor, Inc. (XNCR) reported a net loss of $91.9M for the fiscal year ending 2025.

What is Xencor, Inc.'s operating profit margin?

Xencor, Inc. (XNCR) reported an operating income of $-177.5M, resulting in an operating profit margin of -141.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Xencor, Inc.'s gross profit and gross margin?

Xencor, Inc. (XNCR) generated $115.1M in gross profit for the year, representing a gross profit margin of 91.6%. This demonstrates the company's core pricing power and production efficiency.